Pfizer boosted by sales of its vaccine and its anti-Covid pill

From April to June, the laboratory's turnover jumped 47% to reach 27.74 billion dollars, a record.

Its net profit meanwhile soared 78% to $9.9 billion.

Sales of the vaccine against Covid-19 Comirnaty, developed in collaboration with the German group BioNTech, reached 8.8 billion dollars (+20% compared to the same period in 2021), with an increase in sales in the countries emerging markets and deliveries to certain developed countries.

Deliveries, on the other hand, slowed down in the United States and Canada.

Sales of the anti-Covid pill Paxlovid, launched at the end of 2021 and recently used by US President Joe Biden, for their part reached 8.1 billion dollars.

Without these two products, and without currency effects, Pfizer's sales would have increased by only 1%.

Sales of its smoking cessation treatment Champix have notably been reduced to almost nothing, the group having suspended its distribution due to the excessive presence of a potentially carcinogenic component.

The laboratory maintained its forecasts for the full year, despite a greater than initially expected impact of exchange rate effects on its revenues: the rise in the dollar lowers the value of profits earned abroad when they are converted into US currency.

© 2022 AFP